Daily Tech: Energy, AI, Semiconductors and Biotech Drive Momentum

FutureGate | July 24 2025

OKLO and Liberty Energy Team Up to Deliver Scalable Power Solutions

Nuclear energy startup Oklo Inc. has entered into a strategic alliance with Liberty Energy Inc. (NYSE: LBRT) to co-develop and deploy integrated power solutions for high-demand industrial applications. The collaboration aims to accelerate the commercialization of Oklo’s advanced fission technology, offering off-grid and distributed power systems tailored for industries with significant and consistent energy needs, including mining, oilfield operations, and data centres.

This partnership represents a convergence of clean energy innovation and real-world industrial deployment, positioning both companies at the forefront of the transition toward more reliable, carbon-efficient energy infrastructures. The deal signals institutional confidence in Oklo’s compact fission systems and Liberty’s market reach among energy-intensive clients.

SK Hynix Delivers Strong Earnings on AI Tailwinds

South Korean memory chipmaker SK Hynix reported a robust 69% year-over-year increase in second-quarter profit, reflecting surging demand from the artificial intelligence (AI) and high-performance computing sectors. The firm, a critical supplier to Nvidia, has benefitted from the ongoing boom in generative AI infrastructure, which requires high-bandwidth memory (HBM) and advanced DRAM technologies.

SK Hynix’s results underscore the structural shift in global semiconductor demand toward AI-centric applications. As Nvidia ramps up production of its latest AI accelerators, SK Hynix remains a key beneficiary of the supply chain, reinforcing its strategic relevance in the global chip ecosystem.

Hyperfine Expands AI Imaging Rollout with FDA-Cleared Optive AI™

Medical technology company Hyperfine Inc. (HYPR) has begun nationwide deployment of its newly FDA-cleared Optive AI™ software to existing Swoop® portable MRI systems across hospitals and neurology clinics in the U.S. The software, cleared in late May 2025, significantly enhances imaging capabilities by improving noise cancellation, image acquisition speed, and post-processing efficiency.

This rollout represents a meaningful leap forward in making high-quality neuroimaging more accessible and operationally efficient in non-traditional clinical settings. The combination of portable hardware and AI-augmented software enables faster diagnostics, particularly in emergency care and rural health environments—areas historically underserved by advanced imaging solutions.

Sutro Biopharma Partners with FDA to Advance ADC Regulatory Science

Sutro Biopharma (NASDAQ: STRO) announced a collaborative initiative with the U.S. Food and Drug Administration (FDA) to develop improved reference materials and analytical standards for antibody-drug conjugates (ADCs), leveraging its proprietary XpressCF® cell-free protein synthesis platform. The partnership aims to refine and elevate the regulatory review process for ADCs, which are increasingly viewed as a next-generation therapeutic modality in oncology.

By contributing its platform and scientific expertise, Sutro is playing a pivotal role in modernizing the regulatory environment around complex biologics. This move not only validates Sutro’s leadership in the ADC space but also aligns with a broader industry push for standardized, high-resolution characterization techniques for biologic therapies.